New, Potential First-in-Class Schizophrenia Medicine Reduced Positive and Negative Symptoms in Phase 3 Trial
A new medicine for treating schizophrenia—one that appears to help reduce both positive and negative symptoms of the illness—has passed a first hurdle in phase 3 clinical testing. Phase 3 is often… Read More
Researchers Propose a New Understanding of Dopamine's Role in Learning and Memory
A team led by BBRF grantees has proposed a markedly new way of understanding the role of dopamine in the brain in processes involved in learning and memory. The revised view of the neurotransmitter… Read More
Researchers Explore Whether L-DOPA Can Help PTSD Patients Learn to Extinguish Fear Memories
A team of researchers has reported progress in testing a new approach involving the dopamine system that they hope may help reduce symptoms of post-traumatic stress disorder (PTSD). Read More
Drugs Targeting the Glutamate System Warrant Continued Development for Schizophrenia, Study Finds
In the continuing effort to develop new medicines to treat schizophrenia, a team led by BBRF Scientific Council member Jeffrey Lieberman, M.D., and including nine other Council Members, BBRF grantees… Read More
New Class of Drugs Shows Promise for the Treatment of Schizophrenia
By inhibiting a previously untargeted nerve-cell receptor in the brain, researchers have discovered a new class of compounds that may be useful in the treatment of schizophrenia. In animal models of… Read More